NCT00998049View on ClinicalTrials.gov

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

November 30, 2011

Study Completion Date

April 30, 2015

Conditions
Multiple MyelomaRefractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
Interventions
DRUG

plerixafor

Plerixafor 160mg/kg/dose by IV on days 5-8

DRUG

filgrastim

Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.

Trial Locations (2)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER